Regeneron Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc.: A Comprehensive Revenue Analysis

Biotech Giants: Regeneron vs. Halozyme Revenue Growth

__timestampHalozyme Therapeutics, Inc.Regeneron Pharmaceuticals, Inc.
Wednesday, January 1, 2014753340002819557000
Thursday, January 1, 20151350570004103728000
Friday, January 1, 20161466910004860427000
Sunday, January 1, 20173166130005872227000
Monday, January 1, 20181518620006710800000
Tuesday, January 1, 20191959920007863400000
Wednesday, January 1, 20202675940008497100000
Friday, January 1, 202144331000016071700000
Saturday, January 1, 202266011600012172900000
Sunday, January 1, 202382925300013117200000
Monday, January 1, 2024101532400014202000000
Loading chart...

In pursuit of knowledge

A Decade of Growth: Regeneron vs. Halozyme

In the ever-evolving landscape of biotechnology, Regeneron Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc. have emerged as key players. Over the past decade, Regeneron has consistently outperformed Halozyme, with revenues peaking at approximately $13.1 billion in 2023, a staggering 365% increase from 2014. In contrast, Halozyme's revenue growth, while impressive, saw a more modest rise of around 1,000% over the same period, reaching $829 million in 2023.

Key Insights

  • Regeneron's Dominance: By 2021, Regeneron's revenue had surged to over $16 billion, marking a pivotal year in its financial trajectory.
  • Halozyme's Steady Climb: Despite starting from a lower base, Halozyme's revenue growth reflects its strategic advancements in the biotech sector.

This analysis underscores the dynamic nature of the biotech industry, where innovation and strategic foresight drive financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025